Clinical case of the non-immunogenic recombinant staphylokinase usage in the treatment of massive pulmonary embolism in patient with genetically determined thrombophilia

Background. Pulmonary embolism is an acute potentially fatal condition caused by blockage of the pulmonary artery by a venous thrombus, especially dangerous in massive form. Every year, up to 300 000 cases of pulmonary embolism are registered in a number of countries with a mortality rate of up to 30%. Hereditary thrombophilia, a condition associated with a genetically determined tendency to thrombosis, is of particular importance in the pathogenesis of PE.

Results. In the presented clinical case, the use of the non-immunogenic recombinant staphylokinase contributed to rapid thrombus lysis and stabilization of the patient with massive pulmonary embolism. Thrombolytic therapy made it possible to restore the patency of the pulmonary arteries, preventing the development of complications and ensuring a favorable outcome. Clinical indicators have demonstrated positive dynamics, which confirms the effectiveness of the drug in the treatment of massive pulmonary embolism in patients with a genetic predisposition to thrombosis.

Conclusion. The use of the non-immunogenic recombinant staphylokinase has shown high efficacy in the treatment of massive pulmonary embolism, contributing to the improvement of hemodynamics and stabilization of the patient's condition. Nevertheless, patients with hereditary thrombophilia require a comprehensive approach, including anticoagulant therapy to prevent recurrence of thrombosis. The clinical case highlights the importance of an individualized approach to the treatment and monitoring of patients at high risk of thrombosis to improve the quality and safety of therapy.

1. Nikulina N. N., Terekhovskaya Yu. V. Epidemiology of pulmonary artery thromboembolism in the modern world: analysis of morbidity, mortality and problems of their study. Rossiiskii kardiologicheskii zhurnal. 2019. 6: 103-108. (In Russ.)

2. Konstantinov S. L., Stryabkova G. I., Basarab A. I., Kravchuk V. N., et al. Nonimmunogenic staphylokinase in the treatment of high-risk massive pulmonary artery thromboembolism in the early postoperative period for shrapnel wound of the thigh. Ratsionalnaya farmakoterapiya v kardiologii. 2023; 19 (5): 495-501. (In Russ.)

3. Poponina T. M., Poponina Yu. S., Ryabov V. V. Recurrent course of pulmonary embolism and acute myocardial infarction without ST-segment elevation: current problems of diagnosis and treatment (clinical case). Sibirskii zhurnal klinicheskoi i eksperimentalnoi meditsiny. 2024; 39 (1): 194-201. (In Russ.)

4. Gusina A. A., Gusina N. B. Genetic defects of pro- and anticoagulant proteins as risk factors for venous thrombosis. Meditsinskie novosti. 2006; 9: 10-14. (In Russ.)

5. Kirienko A. I., Leontev S. G., Yarovaya E. B., et al. Non-Immunogenic Staphylokinase vs Alteplase in Patients with Massive Pulmonary Embolism: the Protocol of a Multiple-Center Open-Label Randomized Trial FORPE. Rossiiskii kardiologicheskii zhurnal. 2024; 29 (11): 6157. (In Russ.)

6. Kirienko A. I., Leontyev S. G., Tereschenko S. H., et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomised open-label, multicenter, parallel-group, non-inferiority trial FORPE. Journal of Thrombosis and Haemostasis. 2025; 23 (2): 657-667.

7. Ilyukhin E. A., Prokhorov G. G., Zhirnovoi V. M. Thrombophilia and venous thrombosis (literature review). Statsionarozameshhayuschiye tekhnologii: Ambulatornaya khirurgiya. 2006; 3: 2-6. (In Russ.)

8. Kryuchkova N. M., Chernova A. A., Nikulina S. Yu., Maksimov V. N. Genetic factors in the development of pulmonary artery thromboembolism. Rossiiskii kardiologicheskii zhurnal. 2022; 27 (10): 5173. (In Russ.)

9. Fedorchenko Yu. L., Koreneva T. A., Rogate T. B., Rabinovich E. L., et al. Massive pulmonary embolism in a young woman with hereditary thrombophilia. Dalnevostochnyi meditsinskii zhurnal. 2016; 3: 130-133. (In Russ.)

10. Myalenka E. V., Churilov L. P., Yablonsky P. K. Assessment of the frequency of registration of the main hereditary forms of thrombophilia in pulmonary artery thromboembolism taking into account the sex of patients. Krymskii zhurnal eksperimentalnoy i klinicheskoi meditsiny. 2016; 6 (4): 27-35. (In Russ.)

11. Thromboembolism of the pulmonary artery. Classical diagnosis, the latest methods of prevention and treatment: a guide for doctors. under the general editorship of Academician of the Russian Academy of Sciences L. S. Kokov. Moscow: RAS, 2022; p. 378. (In Russ.)

12. Oana V., Badulescu P., Sirbu D., Filip N. Hereditary Thrombophilia in the Era of COVID-19. Healthcare. 2022; 10 (6): 993-993.